Senti Bio's Cancer Treatment Gets Major FDA Recognition
Senti Bio receives FDA's RMAT designation for SENTI-202, a breakthrough cell therapy showing promising results in treating relapsed acute myeloid leukemia patients.
/ 2 items
Senti Bio receives FDA's RMAT designation for SENTI-202, a breakthrough cell therapy showing promising results in treating relapsed acute myeloid leukemia patients.
H.C. Wainwright initiates Senti Bio with Buy rating and $12 target. Cancer therapy developer's CAR-NK platform shows promise for blood cancers and solid tumors.